tbuckley/cabot-search huggingface dataset:
The 40-Hz Auditory Steady-State Response in Patients With Schizophrenia
Authors: Hanna Thuné, Marc Recasens, Peter J. Uhlhaas
Journal: JAMA Psychiatry (2016)

The neurobiological mechanisms underlying circuit dysfunctions in schizophrenia remain poorly understood. The 40-Hz auditory steady-state response (ASSR) has been suggested as a potential biomarker for schizophrenia.To provide a meta-analytical insight into the presence of 40-Hz ASSR impairments in patients with schizophrenia and to examine the effects of the participant group, stimulus parameters, and analysis and recording techniques.Searches were conducted in PubMed and reference lists of appropriate publications to identify relevant studies published from November 1999 to March 2016. Initial literature searches were performed with combinations of the following search terms: (1) auditory steady state response, (2) schizophrenia, (3) 40 Hz, (4) EEG, (5) MEG, and (6) steady state response.Original articles reporting 40-Hz ASSR data on patients with schizophrenia (chronic or first episode) compared with healthy controls using electroencephalographic (EEG) and magnetoencephalographic (MEG) recordings.Hedges g effect sizes were calculated using sample sizes, P values, and/or Cohen d effect sizes from 20 studies. Effect size data were pooled using random-effects models. Publication bias was corrected for using funnel plots, the Egger regression test, and a trim and fill test. The contributions of study design parameters and participant characteristics were assessed using a mixed linear model approach and subsequent post hoc t tests. The present analysis was performed during the period from November 2015 to March 2016.Random model Hedges g effect sizes for auditory steady-state amplitude and phase-locking measures from sensor/electrode and sources-space responses in EEG and MEG studies.Of the 20 studies analyzed (representing a total of 590 healthy controls and 606 patients with schizophrenia), 17 reported significant reductions in 40-Hz ASSR spectral power and/or phase locking in patients with schizophrenia compared with healthy controls (Hedges g effect: -0.58 [power] and -0.46 [phase]). Effect sizes from spectral power and phase-locking measures did not differ significantly (95% CI, -0.49 to 0.22; t = -0.80; P = .43). Stimulus characteristics and analysis methods were not associated with the findings of 40-Hz ASSR impairment in schizophrenia.The 40-Hz ASSR spectral power and phase-locking deficits are robust in schizophrenia, which suggests that these measures could be useful probes for assessing circuit dysfunctions in the disorder. Moreover, these findings should motivate large-scale studies of the longitudinal expression in patients with schizophrenia and at-risk populations, to further validate the 40-Hz ASSR as a potential biomarker.
BCL-2 and c-MYC Rearrangements in Leukemic Phase of Diffuse Large B Cell Lymphoma Predicts Central Nervous System Involvement
Authors: Yi Shuhua, Shizheng Zhong, Dehui Zou, Chengwen Li, Zengjun Li, Wei Liu, Rui Lv, Peihong Zhang, Huishu Chen, Huijun Wang, Lugui Qiu
Journal: Blood (2014)
Beyond open data: realising the health benefits of sharing data: Table 1
Authors: Elizabeth Pisani, Peter Aaby, J Gabrielle Breugelmans, David Carr, Trish Groves, Michelle Helinski, Dorcas Kamuya, Steven Kern, Katherine Littler, Vicki Marsh, Souleymane Mboup, Laura Merson, Osman Sankoh, Micaela Serafini, Martin Schneider, Vreni Schoenenberger, Philippe J Guerin
Journal: BMJ (2016)

Thank you for your interest in spreading the word about The BMJ.NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address. Username * Your Email * Send To * You are going to email the following Beyond open data: realising the health benefits of sharing data Your Personal Message CAPTCHA This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
A Somatic Variant in MYD88 (L265P) Revealed by Whole Genome Sequencing Differentiates Lymphoplasmacytic Lymphoma From Marginal Zone Lymphomas
Authors: Lian Xu, Aliyah R. Sohani, Luca Arcaini, Zachary Hunter, Guang Yang, Yangsheng Zhou, Xia Liu, Yang Cao, Robert Manning, Christopher J Patterson, Leukothea Ioakimidis, Christina Tripsas, Geraldine S. Pinkus, Nancy Lee Harris, Scott J. Rodig, Steven Treon
Journal: Blood (2011)
GW27-e0526 Plasma level of big endothelin-1 in patients with hypertrophic cardiomyopathy
Authors: Wang Yilu, Yubao Zou, Xiaoliang Luo, Lianming Kang, Dong Wang, Guixin Wu, Hu Wang, Rutai Hui, Jizheng Wang, Yida Tang, Lei Song
Journal: Journal of the American College of Cardiology (2016)
Clinical and Translational Results from a Phase II Trial of Imprime PGG, Alemtuzumab, and Rituximab in the Early Treatment of Patients with High Risk Chronic Lymphocytic Leukemia
Authors: Nandita Bose, Clive S. Zent, Betsy R. LaPlant, Nadine Ottoson, Steven Leonardo, George J Weiner, Stephen M. Ansell
Journal: Blood (2014)
GW27-e0190 The Effects of Acute STEMI Clinical Pathway in the Treatment of Emergency PCI
Authors: Yijun Zhou, Zi Ye, Zhenhua Huang, Peng Jiang, Xiaoyong Xiao, Zhihao Liu, Yan Xiong, Jinli Liao, Yingxiong Huang, Wanwan Zhang, Hong Zhan
Journal: Journal of the American College of Cardiology (2016)
FDG DOTANOC Mismatch in In Vivo Characterization and Grading of Neuroendocrine Tumor
Authors: Anirban Mukherjee, Krishan Kant Agarwal, Chandrasekhar Bal, Rakesh Kumar
Journal: Clinical Nuclear Medicine (2016)

Neuroendocrine tumors (NETs) are rare heterogeneous neoplasm of variable aggressiveness. A 55-year-old woman underwent 68Ga-DOTANOC PET-CT for suspected NET, which revealed DOTANOC-avid soft tissue mass in the second part of the duodenum with multiple hepatic metastases. Another non–DOTANOC-avid abdominal mass and hypodense lesion in segment VI of the liver were noted. For further evaluation, FDG PET-CT was performed, which revealed increased uptake in the abdominal mass and lesion in segment VI of the liver. Biopsy from the previously mentioned lesions revealed poorly differentiated high-grade NET.
Prostate-Specific Membrane Antigen PET/CT Findings for Hepatic Hemangioma
Authors: Hemant Bhardwaj, Maximilian Stephens, Manoj Bhatt, Paul Anthony Thomas
Journal: Clinical Nuclear Medicine (2016)

We report a case of a benign liver hemangioma with intense prostate-specific membrane antigen (PSMA) uptake on Ga PET/CT. A 77-year-old man with prostate adenocarcinoma underwent routine staging with PSMA PET/CT. This revealed an intensely PSMA-avid liver lesion. The known prostate adenocarcinoma was localized and had mild uptake. Diagnostic CT and MRI were characteristic of a hemangioma without interval growth over a 3-month period. PSMA PET/CT is becoming increasingly popular for staging in prostate cancer, and the presence of PSMA uptake in extra-prostatic tumors is being increasingly documented.
TCT-182 One-year Outcomes With Prasugrel (Pre-)Treatment in Routine Practice: Early Results from the Dutch, Multicenter and Observational Rijnmond Collective Cardiology Research (CCR) Study
Authors: Tuncay Yetgin, Arie G. de Vries, Pieter C. Smits, Eric Boersma, Robert J. Van Geuns, Felix Zijlstra, Marc van der Linden
Journal: Journal of the American College of Cardiology (2015)
Upregulated TCR Zeta and Improved the IFN-γ Secretion and Cytotoxicity in T Cell from Patients with AML after IL-2, IL-7 and IL-12 Stimulation
Authors: Shaohua Chen, Li Shi, Lijian Yang, Yuhong Lu, Gengxin Luo, Kanger Zhu, Yangqiu Li
Journal: Blood (2014)
Experience of neoadjuvant regional chemotherapy and biotherapy in the treatment for colorectal liver metastases
Authors: A. F. Lazarev, A. G. Kotelnikov, K. G. Mamontov, A. V. Belonozhka, A. A. Karpenko, A. A. Ponomarenko, V. D. Petrova, E. L. Sekerzhinskaya, S. A. Terekhova
Journal: Journal of Clinical Oncology (2008)

15105 Background: Liver metastases is frequent cause of death of patients with colorectal cancer during the first 2 years. Chemotherapy and liver surgery do not have significant influence on survival. Methods: To improve the effectiveness of treatment of patients with colorectal liver metastases a new method of neo-adjuvant chemo- and biotherapy was designed in Altai oncological centre. 26 patients underwent combined therapy for colorectal cancer with liver metastases. A single solitary liver metastasis was diagnosed in 10 patients, multiple metastases - in 16. 14 patients had bilobed involvement. The largest of metastases were from 4.5 to 25 cm in diameter. 4 patients got 3 courses of neo-adjuvant chemotherapy FOLFOX 6 followed by three-hour infusion of bevacizumab (Avastin) 5mg/m2 via hepatic artery. 22 patients got chemotherapy in the same regimen but without bevacizumab. In a month all the patients had the surgery for liver metastases: 11 patients underwent hemihepatectomy, 1 - extended hemihepatectomy, 4 - hemihepatectomy with resection of other lobe of liver, 1 - limited resection of the liver. Then the patients got the same chemo- and biotherapy. Results: The effectiveness of the preoperative therapy was: 15.4% - partial response, 53.8% - stable disease, 30.8% - tumour progression. 11 patients had postoperative complications, 1 - died of them. None of those who got Avastin before surgery had complications. To the end of he first year all the patients survived (100%). 2-years survival for the present moment amounted 61.0±18.0% (Kaplan-Meier method). None of those who got Avastin in the neo-adjuvant regimen progressed. Conclusion: These data suggest that intraarterial chemo- and biotherapy in neo-adjuvant regimen improved the results of the surgery for colorectal liver metastases and served as preventative measure for recurring dissemination of the tumour in the residuary lobe of liver in the nearest 2 year, and did not entail increasing of complications and lethality. No significant financial relationships to disclose.
Helicase CHD4 is an epigenetic coregulator of PAX3-FOXO1 in alveolar rhabdomyosarcoma
Authors: Maria Böhm, Marco Wachtel, Joana G. Marques, Natalie Streiff, Dominik Laubscher, Paolo Nanni, Kamel Mamchaoui, Raffaella Santoro, Beat W. Schäfer
Journal: Journal of Clinical Investigation (2016)

A vast number of cancer genes are transcription factors that drive tumorigenesis as oncogenic fusion proteins. Although the direct targeting of transcription factors remains challenging, therapies aimed at oncogenic fusion proteins are attractive as potential treatments for cancer. There is particular interest in targeting the oncogenic PAX3-FOXO1 fusion transcription factor, which induces alveolar rhabdomyosarcoma (aRMS), an aggressive cancer of skeletal muscle cells for which patient outcomes remain dismal. In this work, we have defined the interactome of PAX3-FOXO1 and screened 60 candidate interactors using siRNA-mediated depletion to identify candidates that affect fusion protein activity in aRMS cells. We report that chromodomain helicase DNA binding protein 4 (CHD4), an ATP-dependent chromatin remodeler, acts as crucial coregulator of PAX3-FOXO1 activity. CHD4 interacts with PAX3-FOXO1 via short DNA fragments. Together, they bind to regulatory regions of PAX3-FOXO1 target genes. Gene expression analysis suggested that CHD4 coregulatory activity is essential for a subset of PAX3-FOXO1 target genes. Depletion of CHD4 reduced cell viability of fusion-positive but not of fusion-negative RMS in vitro, which resembled loss of PAX3-FOXO1. It also caused specific regression of fusion-positive xenograft tumors in vivo. Therefore, this work identifies CHD4 as an epigenetic coregulator of PAX3-FOXO1 activity, providing rational evidence for CHD4 as a potential therapeutic target in aRMS.
Role and Prognostic Utility of Cutaneous CCL27 Expression in Early Stage Micosys Fungoides
Authors: Gaia Goteri, Serena Rupoli, Lucia Canafoglia, Paola Picardi, Stefano Pulini, Simonetta Mulattieri, Anna Rita Scortechini, Anna Campanati, Giorgio Filosa, Marco Simonacci, Giuseppe Ricotti, Alfredo Giacchetti, Ivana Cataldi, Giuliano Brandozzi, Pietro Leoni
Journal: Blood (2008)
Understanding the Role of <i>P</i> Values and Hypothesis Tests in Clinical Research
Authors: Daniel B. Mark, Kerry L. Lee, Frank E. Harrell
Journal: JAMA Cardiology (2016)

P values and hypothesis testing methods are frequently misused in clinical research. Much of this misuse appears to be owing to the widespread, mistaken belief that they provide simple, reliable, and objective triage tools for separating the true and important from the untrue or unimportant. The primary focus in interpreting therapeutic clinical research data should be on the treatment ("oomph") effect, a metaphorical force that moves patients given an effective treatment to a different clinical state relative to their control counterparts. This effect is assessed using 2 complementary types of statistical measures calculated from the data, namely, effect magnitude or size and precision of the effect size. In a randomized trial, effect size is often summarized using constructs, such as odds ratios, hazard ratios, relative risks, or adverse event rate differences. How large a treatment effect has to be to be consequential is a matter for clinical judgment. The precision of the effect size (conceptually related to the amount of spread in the data) is usually addressed with confidence intervals. P values (significance tests) were first proposed as an informal heuristic to help assess how "unexpected" the observed effect size was if the true state of nature was no effect or no difference. Hypothesis testing was a modification of the significance test approach that envisioned controlling the false-positive rate of study results over many (hypothetical) repetitions of the experiment of interest. Both can be helpful but, by themselves, provide only a tunnel vision perspective on study results that ignores the clinical effects the study was conducted to measure.
Effect of adjuvant radiotherapy on survival in localized limb or trunk wall well-differentiated liposarcoma (WDLPS).
Authors: A. Duret, E. Stoeckle, S. Bonvalot, A. Italiano, S. Piperno-Neumann, G. Kantor, C. le Pechoux, L. Guillou, J. Coindre, J. Blay
Journal: Journal of Clinical Oncology (2010)

10079 Background: WDLPS accounts for about 10% of all soft tissue sarcoma and may arise in any part of the body. Whether post operative radiotherapy is useful in the management of these patients after definitive surgery remains unclear. Methods: Searching the online virtual Conticanet tumor bank conticabase, 195 patients with parietal trunk or extremities WDLPS with pathological central review within the French Sarcoma Group pathologist working party were identified. Dedifferentiated, myxoid/round cell and pleomorphic LPS were excluded. Patient had had primary surgery between 1980 and 2008 in 17 French and Swiss medical centers. Prognostic factors for RFS and OS were investigated in univariate and multivariate analysis, including the use of adjuvant external bean radiotherapy (EBR) mostly given in 2gy fractions over 50-60. Results: 96 males and 99 females, with a median age of 60 were identified. Primary sites were lower limb (156, 80%), trunk wall (15, 8%), groin / shoulder girdles (14, 7%), upper limb (10, 5%). Median size of the primary was 17cm (range 3-40). 163 (84%) pts were followed since the first event, 32 (16%) had had prior surgery on the same tumor. 78 (40%), 76 (39%), 4 (2%) had R0, R1, and R2 resection as first treatment respectively, 103 (53%) patients received postoperative radiotherapy (EBR). 163 patients had a primary surgery in a sarcoma center, and 32 had primary surgery in a primary care center. With a median follow-up of 87 months there were 14 deaths, 15 local relapses, no metastatic relapse.Only EBR and proximal/trunk sites were found significantly associated with RFS in univariate analyses, for both the whole series, and the series of patients treated in reference centers. EBR was the only independent parameter for RFS in multivariate analysis. In the group of 163 patients operated upfront in sarcoma centers, gender, age, trunk/proximal sites, R2 resection, EBR, were retained as independent prognostic factors for overall survival in multivariate analysis, along with, primary surgery in a sarcoma center in the whole series. Conclusions: In this series of 195 WDLPS, relapses occurred only locally and post operative radiotherapy was associated with an improved RFS and overall survival. No significant financial relationships to disclose.
AZD2281 (KU-0059436), a PARP (poly ADP-ribose polymerase) inhibitor with single agent anticancer activity in patients with BRCA deficient ovarian cancer: Results from a phase I study
Authors: P. C. Fong, D. S. Boss, C. P. Carden, M. Roelvink, J. De Greve, C. M. Gourley, J. Carmichael, J. S. De Bono, J. H. Schellens, S. B. Kaye
Journal: Journal of Clinical Oncology (2008)

5510 Background: AZD2281 is a novel, potent orally active PARP inhibitor. It induces cancer specific synthetic lethality in homologous recombination repair defective cells, including BRCA-deficient tumors. We previously reported a first-in-human Phase I trial, with dose escalation guided by toxicity, pharmacokinetic and pharmacodynamic (PD) data (Yap et al, ASCO 2007 Abstr 3529). Method: Initial dose escalation phase included patients (p) with a wide range of drug-resistant cancers. Once a PD active dose was identified, enrichment of the population with p with BRCA-deficient tumors was encouraged. Doses started from 10mg daily for 2 of 3 weeks, escalating to 600mg bd continuously. After the maximum tolerated dose (400mg bd) was identified, an expansion phase in BRCA-deficient ovarian cancer (BDOC) at 200mg bd was opened. Results: Of the total 92 p treated, 44 p had BDOC (includes 1 p with compelling family history). Doses received were 40mg daily (1 p), 100mg bd (3 p), 200mg bd (34 p), 400mg bd (5 p) and 600mg bd (1 p). Toxicities were mainly gastrointestinal and mild, with little myelosuppression seen. 1 p at 400mg bd had a dose limiting neurocognitive toxicity. 32 p with BDOC, the majority of whom were platinum resistant/refractory are so far evaluable for response. All evaluable p had either received treatment for at least 8 weeks (2 cycles) or progressed prior to completion of 2 cycles. 14 p have achieved partial response, 13 meeting GCIG- CA125 criteria and 10 meeting RECIST criteria. Of the responders, 1 p has been on drug > 56 weeks whilst 7 p have maintained responses for ≥ 24 weeks. Stable disease (SD) was seen in an additional 8 p, 7 of whom continue on drug and 3 p had SD ≥ 16 weeks. Responses were seen at all dose levels from 100mg bd and above. Conclusion: AZD2281 is well tolerated and has demonstrated compelling activity in patients with BDOC. Responses were seen in all p groups including platinum resistant disease. Updated efficacy data, together with a correlation of potential predictive factors including platinum free interval will be presented on a total planned cohort of 46 p with BDOC. A randomised study in BRCA-deficient ovarian cancer has been planned. Author Disclosure Employment or Leadership Consultant or Advisory Role Stock Ownership Honoraria Research Expert Testimony Other Remuneration Kudos Kudos Kudos Kudos AstraZeneca Oncology AstraZeneca Oncology
Hyperhomocysteinemia in Relation to Total and Cardiovascular Death after Coronary Artery Bypass Grafting. A Prospective Study.
Authors: Domenico Girelli, Nicola Martinelli, Oliviero Olivieri, Elisabetta Trabetti, Francesca Pizzolo, Simonetta Friso, Claudia Bozzini, Ilaria Tenuti, Giovanni Faccini, Valentina Lotto, Pier Franco Pignatti, Alessandro Mazzucco, Roberto Corrocher
Journal: Blood (2005)
TCT-647 Predictors and Clinical Impact of Myocardial Injury Following Transcatheter Aortic Valve Replacement: Insights from a Large Multicenter Registry
Authors: Henrique B. Ribeiro, Luis Nombela-Franco, Antonio J. Munoz-Garcia, Pedro A. Lemos, Ignacio J. Amat-Santos, Vicenç Serra, Fábio Brito, Alexandre Abizaid, Rogério Sarmento-Leite, Rishi Puri, Asim Cheema, Marc Ruel, Fabian Nietlispach, Francesco Maisano, Cesar Moris, Raquel Del Valle, Marina Urena, Omar Abdul-Jawad Altisent, Maria Del Trigo, Francisco Campelo-Parada, Pilar Jimenez-Quevedo, Juan H. Alonso Briales, Hipolito Gutierrez, Bruno Garcia del Blanco, Marco A. Perin, Dimytri A. Siqueira, Guilherme Bernardi, Eric Dumont, Philippe Pibarot, Josep Rodes-Cabau
Journal: Journal of the American College of Cardiology (2015)
TCT-355 An Automated Computational Method for Quantification of Total Fibrous Cap Volume and Mean Fibrous Cap Thickness with Optical Coherence Tomography
Authors: Vincent Woo, Zhi Chen, Taishi Hirai, Joseph R. Weber, Tomas Kovarnik, Andreas Wahle, Milan Sonka, John J. Lopez
Journal: Journal of the American College of Cardiology (2015)
TCT-753 Peri-interventional Complication Rates In Patients Undergoing Carotid Artery Stenting Depending On The Side Of The Stenosis Treated
Authors: Jürgen Kammler, Hermann Blessberger, Klaus Kerschner, Michael Lichtenauer, Thomas Lambert, Karim Saleh, Alexander Nahler, Clemens Steinwender, Alexander Kypta
Journal: Journal of the American College of Cardiology (2015)
More Than Meets the Eye
Authors: John S. Nguyen, Spyridon S. Marinopoulos, Bimal H. Ashar, John A. Flynn
Journal: New England Journal of Medicine (2006)

A 61-year-old woman was hospitalized with a 2-day history of palpitations and dyspnea. She was found to be in atrial fibrillation with a rapid ventricular response, and intravenous diltiazem and a heparin infusion were begun. Her condition improved, but on the third hospital day, she reported feeling weak and nauseated and began passing dark red urine. She did not have a urinary catheter, palpitations, dyspnea, back pain, abdominal pain, dysuria, or dizziness.
TCT-104 Clinical Outcomes of Transcatheter Aortic Valve Replacement for Bicuspid Aortic Valve Stenosis
Authors: Sung-Han Yoon, Thierry Lefevre, Danny Dvir, Jung-Min Ahn, Takahide Arai, Young-Hak Kim, Yusuke Watanabe, Paul Hsien-Li Kao, Gerald Yong, Wei-Hsian Yin, Michael Kang-Yin Lee, Edgar L. Tay, Hyo-Soo Kim, Bernard Chevalier, Marie-Claude Morice, Webb John, Seung-Jung Park
Journal: Journal of the American College of Cardiology (2015)
Hematologic and Cytogenetic Response to Lenalidomide Therapy in an 82 Year Old Female with Acute Myeloid Leukemia (AML) Arising from JAK2V617F Positive, del(5)(q13q33) Myelodysplastic Syndrome (MDS).
Authors: Ruben A. Mesa, Ayalew Tefferi, David P. Steensma
Journal: Blood (2006)
TCT-792 Long Term Follow-up Meta-Analysis of Carotid Stenting Versus Endarterectomy: Different Procedures with a Similar Safety Profile
Authors: Alexandre M. Benjo, Yamini Ayakannu, Christopher White, Sayf Altabaqchali, Cody Williams, Georges EL-Hayek, Rajan Patel
Journal: Journal of the American College of Cardiology (2015)